Literature DB >> 11170134

Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells.

M Aalamian1, G Pirtskhalaishvili, A Nunez, C Esche, G V Shurin, E Huland, H Huland, M R Shurin.   

Abstract

BACKGROUND: The progression of prostate cancer is accompanied by a marked suppression of the immune system, including the apoptotic death of dendritic cells (DC) responsible for the induction of antitumor immunity. In this study, we evaluated whether prostate cancer might inhibit DC generation and maturation in vitro.
METHODS: DC were generated from peripheral blood monocytes in the presence of the human prostate cell line LNCaP or nonmalignant cells, and characterized by light microscopy, FACScan analysis, and ability to stimulate T-cell proliferation.
RESULTS: Prostate cancer significantly inhibited the conversion of monocytes into DC, which was assessed by the expression of DC markers CD1a and CD83. These cells were weak stimulators of T-cell proliferation, suggesting that DC generated in the prostate cancer microenvironment are functionally inhibited.
CONCLUSIONS: Prostate cancer not only kills mature DC, but also inhibits their generation and maturation, resulting in decreased production of antigen-presenting cells and inhibition of their functional activity. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170134     DOI: 10.1002/1097-0045(200101)46:1<68::aid-pros1010>3.0.co;2-2

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  4-1BB protects dendritic cells from prostate cancer-induced apoptosis.

Authors:  Kuang Youlin; Zhang Jianwei; Gou Xin; Zhang Li; Weng Xiaodong; Liu Xiuheng; Zhu Hengchen; Chen Zhiyuan
Journal:  Pathol Oncol Res       Date:  2012-10-16       Impact factor: 3.201

2.  Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Authors:  Hua Zhong; Dmitriy W Gutkin; Baohui Han; Yang Ma; Anton A Keskinov; Michael R Shurin; Galina V Shurin
Journal:  Int J Cancer       Date:  2014-01-20       Impact factor: 7.396

Review 3.  Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

Authors:  Arthur A Hurwitz; Stephanie K Watkins
Journal:  Cancer Immunol Immunother       Date:  2012-01-12       Impact factor: 6.968

Review 4.  Tumor associated regulatory dendritic cells.

Authors:  Yang Ma; Galina V Shurin; Dmitriy W Gutkin; Michael R Shurin
Journal:  Semin Cancer Biol       Date:  2012-03-06       Impact factor: 15.707

5.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Authors:  Stephanie K Watkins; Ziqiang Zhu; Elena Riboldi; Kim A Shafer-Weaver; Katherine E R Stagliano; Martha M Sklavos; Stefan Ambs; Hideo Yagita; Arthur A Hurwitz
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

6.  Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.

Authors:  Eva Wieckowski; Gurkamal S Chatta; Robbie M Mailliard; William Gooding; Karolina Palucka; Jacques Banchereau; Pawel Kalinski
Journal:  Prostate       Date:  2010-08-17       Impact factor: 4.104

7.  Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells.

Authors:  Irina L Tourkova; Galina V Shurin; Soldano Ferrone; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2008-08-28       Impact factor: 6.968

8.  Regulatory dendritic cells: there is more than just immune activation.

Authors:  Susanne V Schmidt; Andrea C Nino-Castro; Joachim L Schultze
Journal:  Front Immunol       Date:  2012-09-04       Impact factor: 7.561

9.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

Review 10.  Dendritic cell defects in the colorectal cancer.

Authors:  Annalisa Legitimo; Rita Consolini; Alessandra Failli; Giulia Orsini; Roberto Spisni
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.